Get the Stockscreener App
189.13
1.03%
1.92
After Hours:
189.13
Biogen Inc stock is traded at $189.13, with a volume of 463.61K.
It is up +1.03% in the last 24 hours and up +6.65% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$187.21
Open:
$187.38
24h Volume:
463.61K
Relative Volume:
0.38
Market Cap:
$27.92B
Revenue:
$9.60B
Net Income/Loss:
$1.37B
P/E Ratio:
20.30
EPS:
9.3182
Net Cash Flow:
$2.32B
1W Performance:
+3.14%
1M Performance:
+6.65%
6M Performance:
+23.27%
1Y Performance:
+55.28%
1-Day Range:
$186.00
$189.69
1-Week Range:
$180.18
$195.98
52-Week Range:
$115.25
$202.41
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
189.13 | 27.64B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
988.87 | 863.14B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.55 | 539.70B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.11 | 368.19B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
181.24 | 284.52B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.15 | 279.37B | 65.59B | 8.93B | 12.36B | 3.5532 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Upgrade | UBS | Neutral → Buy |
| Apr-20-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen Inc. (BIIB) exec exercises RSUs, uses shares for taxes - Stock Titan
Biogen to Participate in the Bank of America Securities 2026 Health Care Conference - Biogen
symbol__ Stock Quote Price and Forecast - CNN
Apellis (APLS) revises executive separation plan tied to Biogen merger - Stock Titan
BIIB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
How Investors Are Reacting To Biogen (BIIB) Earnings Beat, Lower Guidance, And Felzartamab China Deal - simplywall.st
Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Artemis Investment Management LLP Buys Shares of 226,845 Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Freedom Broker upgrades Biogen stock rating on Apellis acquisition By Investing.com - Investing.com Canada
Citigroup Adjusts Biogen Price Target to $200 From $190 - marketscreener.com
Assessing Biogen (BIIB) Valuation After Strong 1 Year Gains And Mixed Longer Term Returns - simplywall.st
H.C. Wainwright reiterates Biogen stock rating on tau therapy trial - Investing.com
Biogen Inc. (NASDAQ:BIIB) Short Interest Up 15.4% in April - MarketBeat
MSN Money - MSN
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Goldman Sachs Adjusts Biogen Price Target to $250 From $238 - marketscreener.com
Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings - Benzinga
Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH) - The Globe and Mail
Biogen Inc. (NASDAQ:BIIB) Q1 2026 Earnings Call Transcript - Insider Monkey
Guggenheim raises Biogen stock price target to $260 on strong Q1 results - Investing.com
Biogen Inc. Stock (US09062X1037): Analyst Rating Changes and Q1 2026 Earnings Preview - AD HOC NEWS
Biogen Inc (BIIB) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
BIIB Forecast, Price Target & Analyst Ratings | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Biogen (BIIB) One Off US$1.1b Loss Tests Bullish Earnings Growth Narrative - simplywall.st
Is Biogen (BIIB) 2.7% Undervalued After Q1 2026? Non-GAAP EPS $3 - GuruFocus
A Look at Biogen Inc (BIIB) After 6.0% Gain -- GF Value $199.82 vs Price $194.38 - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Vanguard Capital Management (NASDAQ: BIIB) reports 10.99M Biogen shares ownership - Stock Titan
Biogen beats estimates as Alzheimer’s drug gains momentum - The Boston Globe
Biogen Inc. (BIIB.US) 1Q Earnings and Revenue Beat Forecasts - AASTOCKS.com
BofA raises Biogen stock price target on solid quarterly results - Investing.com
BofA raises Biogen stock price target on solid quarterly results By Investing.com - Investing.com Canada
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Biogen Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Biogen Q1 2026 slides: EPS beats forecast, Apellis deal to boost growth - Investing.com
Biogen Q1 Earnings Call Highlights - Yahoo Finance
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs - Yahoo Finance
Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge - TechStock²
Earnings call transcript: Biogen Q1 2026 beats expectations with strong EPS and revenue growth - Investing.com
Biogen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Vanguard Group Inc. Has $3.07 Billion Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Reports Strong Q1 Earnings, Raises 2026 EPS Guidan - GuruFocus
Biogen Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BIIB) 2026-04-29 - Seeking Alpha
Biogen (BIIB) Projects Revenue Decline and Adjusts EPS Forecast for 2026 - GuruFocus
Biogen cuts annual profit forecast on acquisition-related charges - marketscreener.com
Biogen trims full-year earnings outlook on BD impact - MSN
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Biogen Q1 Non-GAAP Earnings, Revenue Rise; Cuts 2026 Earnings Outlook - marketscreener.com
Biogen (NASDAQ: BIIB) boosts profit and cash flow, plans $5.6B Apellis buy - Stock Titan
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):